Study links DPP-IV medication to heart failure, hospitalization

Share this article:

A study of Merck's diabetes DPP-IV medication Januvia indicates the treatment may be associated with an increased risk of heart failure coupled with hospitalization. Forbes reports that although a related editorial describes the absolute risk of heart failure with the DPP-IV as “if present at all, appears to be small,” the study's researchers write that the finding could be clinically relevant.

This is the second bit of recent concern for the drug class as a whole–the medications have been scrutinized over the last year-and-a-half over concerns that they could cause pancreatitis, an inflammation which is associated with pancreatic cancer. Regulators in the US and Europe released a middle-of-the-road assessment in February in which neither group could say there was a causal relationship between the drugs and pancreatitis and/or pancreatic cancer, but were going to keep an eye on future data.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.